August 12, 2019 | Vensana Capital® Events

Vensana Capital Co-Organizes 26th Annual Phoenix Conference

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

39

Level I Clinical Trials

31

Strategic Financings

31

Exits by IPO or M&A